# Can Tesamorelin improve mitochondrial function in obese adults with reduced GH?

Canonical source: https://retacompare.com/research/can-tesamorelin-improve-mitochondrial-function-in-obese-adults-with-reduced-gh

Peptide Longevity Q&A · 2014-01-01


    Research indicates that Tesamorelin treatment significantly increases IGF-I levels, which are positively associated with improvements in phosphocreatine recovery. This suggests that Tesamorelin may enhance mitochondrial function in obese individuals with reduced growth hormone secretion.


What the research shows

The study assessed the effects of Tesamorelin, a growth hormone-releasing hormone (GHRH) analog, on mitochondrial function in obese adults who exhibited reduced growth hormone (GH) secretion. Conducted as a 12-month double-blind, randomized, placebo-controlled trial, the research involved 39 obese men and women. The primary outcome measured was phosphocreatine (PCr) recovery after submaximal exercise, evaluated through (31)P magnetic resonance spectroscopy at both baseline and after 12 months of treatment. The results demonstrated that Tesamorelin treatment led to a significantly greater increase in insulin-like growth factor 1 (IGF-I) compared to placebo, indicating a potential link between IGF-I levels and mitochondrial function.


Why it matters for longevity

The findings of this study are significant in the context of aging and metabolic health. As individuals age, GH secretion typically declines, which can negatively impact mitochondrial function and overall metabolic health. By enhancing IGF-I levels, Tesamorelin may help mitigate some of the age-related declines in mitochondrial performance. Improved mitochondrial function is crucial for energy production and metabolic efficiency, which are essential for maintaining healthspan and potentially extending longevity. This research suggests that targeting GH-related pathways could be a promising strategy for addressing metabolic aging and associated health issues.


Key findings at a glance

Tesamorelin significantly increased IGF-I levels compared to placebo (102.9 ± 31.8 μg/L vs 22.8 ± 8.9 μg/L).

Improvements in phosphocreatine recovery (PCr) were positively associated with increases in IGF-I.

The strongest association between IGF-I and PCr recovery was observed in the Tesamorelin group.

Results remained significant after controlling for various demographic and health parameters.

The study highlights the relationship between GH, IGF-I, and mitochondrial function in obese individuals.


How Tesamorelin works (background)

Tesamorelin functions as a synthetic analog of GHRH, which stimulates the pituitary gland to release growth hormone. Increased GH levels subsequently elevate IGF-I production in the liver. IGF-I plays a critical role in various biological processes, including growth, metabolism, and cellular repair. The enhancement of IGF-I through Tesamorelin treatment may lead to improved mitochondrial function, as indicated by the positive correlation with phosphocreatine recovery observed in the study. This mechanism underscores the potential of Tesamorelin in addressing metabolic dysfunctions associated with aging and obesity.


Safety, caveats, and what we don't yet know

While the study presents promising findings, it is essential to acknowledge its limitations. The research was conducted on a specific population of obese individuals with reduced GH, and results may not be generalizable to other demographics, such as non-obese individuals or those with different health conditions. Additionally, the long-term effects of Tesamorelin on mitochondrial function and overall healthspan remain to be fully understood. Further studies are needed to explore the safety profile and efficacy of Tesamorelin in diverse populations and to investigate potential side effects associated with long-term use.


Bottom line

The research suggests that Tesamorelin may improve mitochondrial function by increasing IGF-I levels in obese adults with reduced GH secretion, highlighting its potential role in addressing metabolic aging.


Related questions

Does Tesamorelin enhance metabolic health in older adults?

Research indicates that Tesamorelin may improve metabolic parameters by increasing IGF-I levels, which can enhance mitochondrial function and overall metabolic health in older populations.


How does IGF-I relate to aging and healthspan?

IGF-I is crucial for growth and metabolic regulation. Increased levels of IGF-I, as seen with Tesamorelin treatment, may help counteract some age-related declines in metabolic function.


What are the potential benefits of Tesamorelin beyond mitochondrial function?

Beyond enhancing mitochondrial function, Tesamorelin may have implications for improving body composition, insulin sensitivity, and overall metabolic health, making it a subject of interest in longevity research.


Source: PubMed · J Clin Endocrinol Metab · published 2014-01-01.

## Sources

- PubMed · J Clin Endocrinol Metab: https://pubmed.ncbi.nlm.nih.gov/24178787/